HB 1725 – Shielding patients from medical debt
HB 1725 builds on 2024’s success by furthering protections that ensure: Patients won’t be charged interest or late fees on medical debt Access to affordable payment plans with payments capped […]
FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
December 20, 2024 BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with […]
FDA Approves Bristol Myers Squibb’s Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications
December 27, 2024 Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase […]
FDA Approves BeiGene’s TEVIMBRA® (tislelizumab-jsgr) First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
Dec 27, 2024 6:00 AM New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers […]
HB 1732 – Appropriate Notification for Patients Receiving Life-Changing Test Results
HB 1732 ensures patients receive serious and sensitive medical test results, such as cancer diagnoses or genetic findings, directly from their physician. By implementing a 72-hour delay for these results, it allows physicians time to review, interpret, and provide appropriate context and support, reducing unnecessary patient anxiety and confusion.